Skip to content
FDA.report
Public FDA data
NDC
RxNorm
DailyMed
Applications
GUDID
PMA
PMN
MAUDE
Recalls
Search FDA.report
Search
Home
DailyMed
product-concept
0fc8d6a0-e17e-438b-8b82-328781db0b4c
LAROTRECTINIB SULFATE - Food and Drug Administration
Set ID
0fc8d6a0-e17e-438b-8b82-328781db0b4c
Type
Indexing - product concept
Effective date
2019-03-20
Version
2
Source
DailyMed source
Mapped DailyMed Labels
#
Label, Relation, Manufacturer table
Label
Relation
Manufacturer
Effective
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Product name
Bayer HealthCare Pharmaceuticals Inc.
2026-05-22
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Product name
Bayer HealthCare Pharmaceuticals Inc.
2026-03-02
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Product name
Bayer HealthCare Pharmaceuticals Inc.
2025-04-09
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Product name
Loxo Oncology, Inc. | Penn Pharmaceutical Services Ltd | Albemarle Corporation | Sharp Corporation
2018-12-05
Related NDC Packages
#
NDC, DailyMed label, Manufacturer table
NDC
DailyMed label
Manufacturer
50419-390
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Bayer HealthCare Pharmaceuticals Inc.
50419-390-01
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Bayer HealthCare Pharmaceuticals Inc.
50419-391
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Bayer HealthCare Pharmaceuticals Inc.
50419-391-01
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Bayer HealthCare Pharmaceuticals Inc.
50419-392
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Bayer HealthCare Pharmaceuticals Inc.
50419-392-01
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Bayer HealthCare Pharmaceuticals Inc.
50419-393
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Bayer HealthCare Pharmaceuticals Inc.
50419-393-02
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Bayer HealthCare Pharmaceuticals Inc.
50419-393-03
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Bayer HealthCare Pharmaceuticals Inc.
71777-390
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Loxo Oncology, Inc. | Penn Pharmaceutical Services Ltd | Albemarle Corporation | Sharp Corporation
71777-390-01
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Loxo Oncology, Inc. | Penn Pharmaceutical Services Ltd | Albemarle Corporation | Sharp Corporation
71777-391
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Loxo Oncology, Inc. | Penn Pharmaceutical Services Ltd | Albemarle Corporation | Sharp Corporation
71777-391-01
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Loxo Oncology, Inc. | Penn Pharmaceutical Services Ltd | Albemarle Corporation | Sharp Corporation
71777-392
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Loxo Oncology, Inc. | Penn Pharmaceutical Services Ltd | Albemarle Corporation | Sharp Corporation
71777-392-01
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018
Loxo Oncology, Inc. | Penn Pharmaceutical Services Ltd | Albemarle Corporation | Sharp Corporation